By Kelly Cloonan
Shares of Omeros fell after the company reported lower royalties after sales of its partner Rayner fell.
The stock fell 14% to $3.42 after touching a 52-week low. Shares have risen 3.2% over the past 12 months.
The biopharmaceutical company on Thursday posted a loss of $33.5 million, or 58 cents a share, compared with a loss of $37.2 million, or 63 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 57 cents a share.
The company saw $6.7 million in royalties for its Omidria treatment from Rayner's U.S. sales of $22.3 million, down from royalties of $9.4 million on sales of $31.2 million a year ago.
The company also said it has temporarily paused certain activities to prioritize spending on the launch of narsoplimab, a treatment for transplant-associated thrombotic microangiopathy.
The suspended operations include its Phase 3 trial evaluating zaltenibart, a treatment for paroxysmal nocturnal hemoglobinuria.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 16, 2025 14:32 ET (18:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.